Reviva Pharmaceuticals Holdings, Inc. filings document material-event disclosures for a public pharmaceutical operating company, including 8-K reports on operating and financial results, Regulation FD updates, material agreements, clinical or regulatory matters, capital-structure disclosures, and Nasdaq continued-listing compliance.
The records also cover security-holder rights, certificate or bylaw amendments, registered common stock information, security-structure disclosures, exhibits, press releases, and Inline XBRL cover-page data.
Reviva Pharmaceuticals Holdings, Inc. is the subject of a Schedule 13G/A reporting that CVI Investments, Inc. and Heights Capital Management, Inc. collectively hold 672,811 shares of common stock, representing 4.9% of the class. The filing states these shares "consist of Shares issuable upon the exercise of warrants" and that the warrants are restricted so exercises cannot cause ownership to exceed 4.99%. The company reported 12,810,377 Shares outstanding as of March 27, 2026. The filing is signed on 05/13/2026.
Reviva Pharmaceuticals Holdings, Inc. is the subject of a Schedule 13G/A reporting that CVI Investments, Inc. and Heights Capital Management, Inc. collectively hold 672,811 shares of common stock, representing 4.9% of the class. The filing states these shares "consist of Shares issuable upon the exercise of warrants" and that the warrants are restricted so exercises cannot cause ownership to exceed 4.99%. The company reported 12,810,377 Shares outstanding as of March 27, 2026. The filing is signed on 05/13/2026.
Reviva Pharmaceuticals Holdings files a Schedule 13G reporting Barclays PLC beneficial ownership of 763,579 shares. The filing states Barclays holds 763,579 shares of Reviva common stock (CUSIP 76152G209), representing 5.96% of the class as of 03/31/2026. Barclays is shown with sole voting and sole dispositive power over the same 763,579 shares. The filing names Barclays Bank PLC as the relevant subsidiary and is signed by a director on 05/14/2026.
Reviva Pharmaceuticals Holdings files a Schedule 13G reporting Barclays PLC beneficial ownership of 763,579 shares. The filing states Barclays holds 763,579 shares of Reviva common stock (CUSIP 76152G209), representing 5.96% of the class as of 03/31/2026. Barclays is shown with sole voting and sole dispositive power over the same 763,579 shares. The filing names Barclays Bank PLC as the relevant subsidiary and is signed by a director on 05/14/2026.
Reviva Pharmaceuticals Holdings, Inc. reported a narrower net loss of about $3.2 million for the three months ended March 31, 2026, compared with $6.4 million a year earlier, mainly due to sharply lower research and development spending. R&D expenses fell to roughly $1.4 million from $4.1 million, and general and administrative costs declined to about $1.8 million from $2.4 million.
Cash and cash equivalents increased to $22.2 million as of March 31, 2026, driven by financing activities, including a March 2026 public offering with $10.0 million in gross proceeds and an at-the-market equity program that raised about $2.5 million. Working capital surplus rose to approximately $17.4 million, and total stockholders’ equity more than doubled to about $17.4 million.
The company remains a clinical-stage biotech with no product revenue and an accumulated deficit of roughly $187.3 million. Management states that existing cash is expected to fund operations into early 2027 but explicitly concludes there is substantial doubt about Reviva’s ability to continue as a going concern without additional capital. During the quarter, Reviva also effected a 1‑for‑20 reverse stock split and later received notice that its shares will be delisted from Nasdaq and quoted on the OTCQB Venture Market under “RVPH.”
Reviva Pharmaceuticals Holdings, Inc. reported a narrower net loss of about $3.2 million for the three months ended March 31, 2026, compared with $6.4 million a year earlier, mainly due to sharply lower research and development spending. R&D expenses fell to roughly $1.4 million from $4.1 million, and general and administrative costs declined to about $1.8 million from $2.4 million.
Cash and cash equivalents increased to $22.2 million as of March 31, 2026, driven by financing activities, including a March 2026 public offering with $10.0 million in gross proceeds and an at-the-market equity program that raised about $2.5 million. Working capital surplus rose to approximately $17.4 million, and total stockholders’ equity more than doubled to about $17.4 million.
The company remains a clinical-stage biotech with no product revenue and an accumulated deficit of roughly $187.3 million. Management states that existing cash is expected to fund operations into early 2027 but explicitly concludes there is substantial doubt about Reviva’s ability to continue as a going concern without additional capital. During the quarter, Reviva also effected a 1‑for‑20 reverse stock split and later received notice that its shares will be delisted from Nasdaq and quoted on the OTCQB Venture Market under “RVPH.”
Reviva Pharmaceuticals Holdings, Inc. reported a first quarter 2026 net loss of $3,195,987, about half the $6,432,840 loss a year earlier, as operating expenses fell to $3,271,952 from $6,538,167. Net loss per share narrowed to $0.46 from $2.61, reflecting both lower spending and higher share count.
Cash and cash equivalents rose to $22,190,231 as of March 31, 2026, up from $14,438,792 at year-end, driving total stockholders’ equity to $17,440,481. The company continues to invest in its late-stage CNS pipeline, led by brilaroxazine.
Reviva filed a composition of matter provisional patent application for a new form of brilaroxazine intended to extend commercial exclusivity through 2046. It expects FDA feedback on using this new form in the RECOVER-2 registrational Phase 3 schizophrenia trial and future NDA in mid-2026, with patient enrollment in RECOVER-2 targeted to begin in Q3 2026. Trading of Reviva’s common stock on Nasdaq will be suspended on May 14, 2026, and the shares will be quoted on the OTCQB Venture Market under the symbol RVPH.
Reviva Pharmaceuticals Holdings, Inc. reported a first quarter 2026 net loss of $3,195,987, about half the $6,432,840 loss a year earlier, as operating expenses fell to $3,271,952 from $6,538,167. Net loss per share narrowed to $0.46 from $2.61, reflecting both lower spending and higher share count.
Cash and cash equivalents rose to $22,190,231 as of March 31, 2026, up from $14,438,792 at year-end, driving total stockholders’ equity to $17,440,481. The company continues to invest in its late-stage CNS pipeline, led by brilaroxazine.
Reviva filed a composition of matter provisional patent application for a new form of brilaroxazine intended to extend commercial exclusivity through 2046. It expects FDA feedback on using this new form in the RECOVER-2 registrational Phase 3 schizophrenia trial and future NDA in mid-2026, with patient enrollment in RECOVER-2 targeted to begin in Q3 2026. Trading of Reviva’s common stock on Nasdaq will be suspended on May 14, 2026, and the shares will be quoted on the OTCQB Venture Market under the symbol RVPH.
Reviva Pharmaceuticals Holdings, Inc. reports that its common stock will be delisted from the Nasdaq Capital Market after failing to meet Nasdaq’s minimum bid price requirement of $1.00 per share under Listing Rule 5550(a)(2) by May 11, 2026.
The Nasdaq Hearings Panel notified the company on May 12, 2026 that trading on Nasdaq will be suspended as of the open on May 14, 2026. On the same date, the stock is expected to begin trading on the OTCQB Venture Market under the existing symbol “RVPH.”
The company adds new risk disclosures explaining that the Nasdaq delisting and OTCQB trading may reduce liquidity and market price, limit access to capital and equity incentives, subject the stock to “penny stock” rules, and increase volatility and difficulty for investors seeking to resell shares.
Reviva Pharmaceuticals Holdings, Inc. reports that its common stock will be delisted from the Nasdaq Capital Market after failing to meet Nasdaq’s minimum bid price requirement of $1.00 per share under Listing Rule 5550(a)(2) by May 11, 2026.
The Nasdaq Hearings Panel notified the company on May 12, 2026 that trading on Nasdaq will be suspended as of the open on May 14, 2026. On the same date, the stock is expected to begin trading on the OTCQB Venture Market under the existing symbol “RVPH.”
The company adds new risk disclosures explaining that the Nasdaq delisting and OTCQB trading may reduce liquidity and market price, limit access to capital and equity incentives, subject the stock to “penny stock” rules, and increase volatility and difficulty for investors seeking to resell shares.
UBS Group reports shared ownership of 746,095 shares (5.82%) of Reviva Pharmaceuticals Holdings, Inc. The Schedule 13G discloses that UBS Group and certain wholly owned subsidiaries hold 746,095 shares of common stock, with shared voting and dispositive power over those shares. The filing lists UBS Group's principal office in Zurich and identifies the securities by CUSIP 76152G209. The form is signed by a director on 05/07/2026 and indicates the ownership amount as of 03/31/2026.
UBS Group reports shared ownership of 746,095 shares (5.82%) of Reviva Pharmaceuticals Holdings, Inc. The Schedule 13G discloses that UBS Group and certain wholly owned subsidiaries hold 746,095 shares of common stock, with shared voting and dispositive power over those shares. The filing lists UBS Group's principal office in Zurich and identifies the securities by CUSIP 76152G209. The form is signed by a director on 05/07/2026 and indicates the ownership amount as of 03/31/2026.
Reviva Pharmaceuticals Holdings, Inc. disclosed a joint Schedule 13G filing showing a group of filers—Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander—each reporting 793,952 shares, representing 6.2% of the class.
The filing states these shares are held by entities over which Millennium Management LLC and related managers have voting control and investment discretion. The submission includes a Joint Filing Agreement dated March 27, 2026 and lists the issuer CUSIP 76152G209.
Reviva Pharmaceuticals Holdings, Inc. disclosed a joint Schedule 13G filing showing a group of filers—Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander—each reporting 793,952 shares, representing 6.2% of the class.
The filing states these shares are held by entities over which Millennium Management LLC and related managers have voting control and investment discretion. The submission includes a Joint Filing Agreement dated March 27, 2026 and lists the issuer CUSIP 76152G209.
Reviva Pharmaceuticals Holdings, Inc. reported full year 2025 results, highlighting progress toward late-stage development of brilaroxazine for schizophrenia. The FDA recommended a second Phase 3 trial, and Reviva plans to start the RECOVER-2 registrational study in mid-2026 as part of a future NDA package.
For 2025, Reviva posted a net loss of $19.9 million, improving from a $29.9 million net loss in 2024 as total operating expenses fell to $20.2 million from $30.8 million. Research and development expenses declined to $11.7 million, while general and administrative costs rose modestly to $8.5 million.
Cash and cash equivalents were $14.4 million as of December 31, 2025, slightly above the prior year. Stockholders’ equity increased to $8.6 million, supported by higher additional paid-in capital and a larger share count, with 5,872,865 common shares issued and outstanding at year-end.
Reviva Pharmaceuticals Holdings, Inc. reported full year 2025 results, highlighting progress toward late-stage development of brilaroxazine for schizophrenia. The FDA recommended a second Phase 3 trial, and Reviva plans to start the RECOVER-2 registrational study in mid-2026 as part of a future NDA package.
For 2025, Reviva posted a net loss of $19.9 million, improving from a $29.9 million net loss in 2024 as total operating expenses fell to $20.2 million from $30.8 million. Research and development expenses declined to $11.7 million, while general and administrative costs rose modestly to $8.5 million.
Cash and cash equivalents were $14.4 million as of December 31, 2025, slightly above the prior year. Stockholders’ equity increased to $8.6 million, supported by higher additional paid-in capital and a larger share count, with 5,872,865 common shares issued and outstanding at year-end.
Reviva Pharmaceuticals Holdings, Inc. files its annual report describing a late-stage CNS and inflammatory disease pipeline led by brilaroxazine for schizophrenia. The company reports positive results from a large Phase 3 RECOVER trial and a 12‑month extension showing durable efficacy and generally favorable safety.
FDA has asked Reviva to run an additional Phase 3 schizophrenia study (RECOVER‑2) using 30 mg and 50 mg doses before submitting a new drug application, with trial activities expected to start in 2026 and completion targeted for 2027. Brilaroxazine also holds orphan drug designations for pulmonary arterial hypertension and idiopathic pulmonary fibrosis and has encouraging preclinical data in both.
To support operations and development, Reviva executed a May 2025 at‑the‑market program and a March 2026 public offering, raising cash through common stock, pre‑funded warrants and common warrants. A 1‑for‑20 reverse stock split became effective in March 2026, and shares outstanding were 12,810,377 as of March 27, 2026.
Reviva Pharmaceuticals Holdings, Inc. files its annual report describing a late-stage CNS and inflammatory disease pipeline led by brilaroxazine for schizophrenia. The company reports positive results from a large Phase 3 RECOVER trial and a 12‑month extension showing durable efficacy and generally favorable safety.
FDA has asked Reviva to run an additional Phase 3 schizophrenia study (RECOVER‑2) using 30 mg and 50 mg doses before submitting a new drug application, with trial activities expected to start in 2026 and completion targeted for 2027. Brilaroxazine also holds orphan drug designations for pulmonary arterial hypertension and idiopathic pulmonary fibrosis and has encouraging preclinical data in both.
To support operations and development, Reviva executed a May 2025 at‑the‑market program and a March 2026 public offering, raising cash through common stock, pre‑funded warrants and common warrants. A 1‑for‑20 reverse stock split became effective in March 2026, and shares outstanding were 12,810,377 as of March 27, 2026.
Reviva Pharmaceuticals Holdings, Inc. investor Parag Saxena filed an amended Schedule 13D reporting beneficial ownership of 363,280 shares of common stock, or about 2.8% of the 12,810,377 shares outstanding as of March 20, 2026. His holdings include directly owned shares, interests held through various Vedanta-related entities, shares underlying warrants and pre-funded warrants, and fully vested options exercisable within 60 days of the filing date. The filing states that Saxena ceased to be a beneficial owner of more than five percent of Reviva’s common stock on March 20, 2026, and that he has not effected any transactions in the issuer’s securities during the 60 days preceding this amendment.
Reviva Pharmaceuticals Holdings, Inc. investor Parag Saxena filed an amended Schedule 13D reporting beneficial ownership of 363,280 shares of common stock, or about 2.8% of the 12,810,377 shares outstanding as of March 20, 2026. His holdings include directly owned shares, interests held through various Vedanta-related entities, shares underlying warrants and pre-funded warrants, and fully vested options exercisable within 60 days of the filing date. The filing states that Saxena ceased to be a beneficial owner of more than five percent of Reviva’s common stock on March 20, 2026, and that he has not effected any transactions in the issuer’s securities during the 60 days preceding this amendment.